CSPI criticized the FDA’s plans to convene a Pharmacy Compounding Advisory Committee meeting in July to consider adding seven injectable peptides to what can be compounded. The statement argues that lifting restrictions could expand access to products with limited evidence while creating safety and regulatory incentive problems. The FDA’s action follows ongoing debate about peptides marketed for unproven benefits and concerns that compounding could bypass parts of the standard drug approval pathway. CSPI’s letter cites prior FDA actions banning certain peptides from compounding due to “significant safety risks.” For biotech and compliance teams, the update matters because compounding policy can affect market access, patient exposure to experimental products, and how quickly safety signals are detected and communicated.